These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30768970)

  • 1. Impaired Cytolytic Activity and Loss of Clonal Neoantigens in Elderly Patients With Lung Adenocarcinoma.
    Gong Z; Jia Q; Chen J; Diao X; Gao J; Wang X; Zhu B
    J Thorac Oncol; 2019 May; 14(5):857-866. PubMed ID: 30768970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B7-H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression.
    Lu Y; Wu F; Cao Q; Sun Y; Huang M; Xiao J; Zhou B; Zhang L
    Oncogene; 2022 Jan; 41(5):704-717. PubMed ID: 34839353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and validation of tumor environment phenotypes in lung adenocarcinoma by integrative genome-scale analysis.
    Bi G; Chen Z; Yang X; Liang J; Hu Z; Bian Y; Sui Q; Li R; Zhan C; Fan H
    Cancer Immunol Immunother; 2020 Jul; 69(7):1293-1305. PubMed ID: 32189030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of the immune microenvironment associated with RRM2 expression and its application to PD-L1/PD-1 inhibitors in lung adenocarcinoma.
    Lee SK; Hwang Y; Han JH; Haam S; Lee HW; Koh YW
    Am J Cancer Res; 2023; 13(11):5443-5454. PubMed ID: 38058821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.
    McGranahan N; Furness AJ; Rosenthal R; Ramskov S; Lyngaa R; Saini SK; Jamal-Hanjani M; Wilson GA; Birkbak NJ; Hiley CT; Watkins TB; Shafi S; Murugaesu N; Mitter R; Akarca AU; Linares J; Marafioti T; Henry JY; Van Allen EM; Miao D; Schilling B; Schadendorf D; Garraway LA; Makarov V; Rizvi NA; Snyder A; Hellmann MD; Merghoub T; Wolchok JD; Shukla SA; Wu CJ; Peggs KS; Chan TA; Hadrup SR; Quezada SA; Swanton C
    Science; 2016 Mar; 351(6280):1463-9. PubMed ID: 26940869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis and identification of subtypes and hub genes of high immune response in lung adenocarcinoma.
    Li H; Lei Y; Lai X; Huang R; Xiang Y; Zhao Z; Fang Z; Lai T
    BMC Pulm Med; 2024 Jul; 24(1):324. PubMed ID: 38965571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of CNKSR1 as a biomarker for "cold" tumor microenvironment in lung adenocarcinoma: An integrative analysis based on a novel workflow.
    Cai Q; Peng M
    Heliyon; 2024 Apr; 10(8):e29126. PubMed ID: 38628722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low TP53 variant allele frequency as a biomarker for anti-programmed death (ligand) 1 monotherapy in lung adenocarcinoma.
    Wang S; Xie T; Li Y; Guo L; Ying J; Wang Y; Hao X; Wang X; Li J; Xing P
    Cancer; 2023 Dec; 129(24):3873-3883. PubMed ID: 37538036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TMPRSS2 is a tumor suppressor and its downregulation promotes antitumor immunity and immunotherapy response in lung adenocarcinoma.
    Liu Z; Lu Q; Zhang Z; Feng Q; Wang X
    Respir Res; 2024 Jun; 25(1):238. PubMed ID: 38862975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive value of E2F7 in immunotherapy efficacy for lung adenocarcinoma: An observational study.
    Cui H; Li H; Liu J; Zhao P; Liu Y; Zhong R; Li R; Cheng Y
    Medicine (Baltimore); 2024 Jun; 103(25):e38574. PubMed ID: 38905387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-cell death-related signature reveals tumor immune microenvironment and optimizes personalized therapy alternations in lung adenocarcinoma.
    Han L; He J; Xie H; Gong Y; Xie C
    Sci Rep; 2024 Jul; 14(1):15682. PubMed ID: 38977778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcription Factor ETV4 Activates AURKA to Promote PD-L1 Expression and Mediate Immune Escape in Lung Adenocarcinoma.
    Yang P; He S; Ye L; Weng H
    Int Arch Allergy Immunol; 2024 May; ():1-11. PubMed ID: 38781935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining TIGIT blockade with IL-15 stimulation is a promising immunotherapy strategy for lung adenocarcinoma.
    Luo B; Sun Y; Zhan Q; Luo Y; Chen Y; Fu T; Yang T; Ren L; Xie Z; Situ X; Liu B; Tang K; Ke Z
    Clin Transl Med; 2024 Jan; 14(1):e1553. PubMed ID: 38279870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGL1 in plasma extracellular vesicles is correlated with clinical stage of lung adenocarcinoma and anti-PD-L1 response.
    Zhang Y; Zhang K; Wen H; Ge D; Gu J; Zhang C
    Clin Exp Immunol; 2024 Mar; 216(1):68-79. PubMed ID: 38146642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening and validation of plasma cell-derived, purinergic, and calcium signalling-related genetic signature to predict prognosis and PD-L1/PD-1 blockade responses in lung adenocarcinoma.
    Huang J; Fan X; Hu B; Chen L
    J Cancer Res Clin Oncol; 2023 Nov; 149(14):12931-12945. PubMed ID: 37468608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A mouse model for the study of anti-tumor T cell responses in Kras-driven lung adenocarcinoma.
    Fitzgerald B; Connolly KA; Cui C; Fagerberg E; Mariuzza DL; Hornick NI; Foster GG; William I; Cheung JF; Joshi NS
    Cell Rep Methods; 2021 Sep; 1(5):. PubMed ID: 34632444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. System analysis based on glutamine catabolic-related enzymes identifies GPT2 as a novel immunotherapy target for lung adenocarcinoma.
    Wang B; Pei J; Xu S; Liu J; Yu J
    Comput Biol Med; 2023 Oct; 165():107415. PubMed ID: 37657356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harnessing lipid metabolism modulation for improved immunotherapy outcomes in lung adenocarcinoma.
    Chen Y; Zhou Y; Ren R; Chen Y; Lei J; Li Y
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 38977328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of CDCA5 expression on the immune microenvironment and its potential utility as a biomarker for PD-L1/PD-1 inhibitors in lung adenocarcinoma.
    Koh YW; Hwang Y; Lee SK; Han JH; Haam S; Lee HW
    Transl Oncol; 2024 Aug; 46():102024. PubMed ID: 38838437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Investigation of the Immune Microenvironment and Genome during Lung Adenocarcinoma Development.
    Wang Q; Xie B; Sun J; Li Z; Xiao D; Tao Y; She X
    J Cancer; 2024; 15(6):1687-1700. PubMed ID: 38370388
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.